CytomX Therapeutics, Inc. (CTMX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

4.0800

+0.2500

(+6.53%)

At close: 04:00PM EST

4.0800

0.00

(0.00%)

After hours:

04:02PM EST

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Fast Stochastic

View all chart patterns

Performance Outlook

Previous Close	3.8300
Open	3.8700
Bid	4.0300 x 1000
Ask	4.4700 x 1000
Day's Range	3.8300 - 4.1600
52 Week Range	3.6700 - 10.0500
Volume	1,046,665
Avg. Volume	1,272,672

Market Cap	266.216M
Beta (5Y Monthly)	0.59
PE Ratio (TTM)	N/A
EPS (TTM)	-1.2120
Earnings Date	Feb 22, 2022 - Feb 28, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	12.25

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CTMX

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

CytomX Therapeutics, Inc.
Analyst Report: Seagen Inc.Seagen Inc. (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen’s therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
Rating
Fair Value
Economic Moat
2 days agoMorningstar

All

News

Press Releases

Research Reports

GlobeNewswire
CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors
- CX-904 is CytomX’s first T-cell-engaging bispecific antibody and the sixth Probody® therapeutic candidate to enter the clinic -SOUTH SAN FRANCISCO, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for CX-904, an EGFRxCD3 T-cell-engaging bispecific antibody being co-
- Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer
  GlobeNewswire
- Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors
  Business Wire
Insider Monkey
10 Small-Cap Stocks to Buy According to Billionaire Steve Cohen
In this article, we discuss the 10 small-cap stocks to buy according to billionaire Steve Cohen. You can skip our detailed analysis of Steve Cohen’s hedge fund, and go directly to read 5 Small-Cap Stocks to Buy According to Billionaire Steve Cohen. Billionaire investor Steve Cohen is the brain behind Point72 Asset Management, a hedge fund […]
GlobeNewswire
CytomX Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12th at 3:00 p.m. ET. A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.